Revision as of 19:40, 24 January 2013 by Vishnu Vardhan Serla(talk | contribs)(/* Periprocedural Management of Patients Undergoing Carotid Endarterectomy (DO NOT EDIT){{cite journal| author=Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL et al.| title=2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNI...)
The safety and efficacy of carotid revascularization before or concurrent with myocardial revascularization are not well established.
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS: Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease (DO NOT EDIT)[1]
Selection of Patients for Carotid Revascularization (DO NOT EDIT)[1]
"2. CAS is indicated as an alternative to CEA for symptomatic patients at average or low risk of complications associated with endovascular intervention when the diameter of the lumen of the internal carotid artery is reduced by more than 70% as documented by noninvasive imaging or more than 50% as documented by catheterangiography and the anticipated rate of periprocedural stroke or mortality is less than 6%.[5](Level of Evidence: B) "
"3. Selection of asymptomatic patients for carotid revascularization should be guided by an assessment of comorbid conditions, life expectancy, and other individual factors and should include a thorough discussion of the risks and benefits of the procedure with an understanding of patient preferences. (Level of Evidence: C) "
"3. Carotid revascularization is not recommended for patients with severe disability caused by cerebral infarction that precludes preservation of useful function. (Level of Evidence: C) "
"3. It is reasonable to choose CAS over CEA when revascularization is indicated in patients with neck anatomy unfavorable for arterial surgery.[7][19][20][21](Level of Evidence: B) "
"4. When revascularization is indicated for patients with TIA or stroke and there are no contraindications to early revascularization, intervention within 2 weeks of the index event is reasonable rather than delaying surgery.[22](Level of Evidence: B) "
"1. Prophylactic CAS might be considered in highly selected patients with asymptomatic carotid stenosis (minimum 60% by angiography, 70% by validated Doppler ultrasound), but its effectiveness compared with medical therapy alone in this situation is not well established.[5](Level of Evidence: B) "
"2. Beyond the first month after CEA, aspirin (75 to 325 mg daily), clopidogrel (75 mg daily), or the combination of low-dose aspirin plus extended-release dipyridamole (25 and 200 mg twice daily, respectively) should be administered for long-term prophylaxis against ischemic cardiovascular events[27][28][29]. (Level of Evidence: B) "
"3. Administration of antihypertensive medication is recommended as needed to control blood pressure before and after CEA. (Level of Evidence: C) "
"4. The findings on clinical neurological examination should be documented within 24 hours before and after CEA. (Level of Evidence: C) "
"1. Patch angioplasty can be beneficial for closure of the arteriotomy after CEA[30][31]. (Level of Evidence: B) "
"2. Administration of statin lipid-lowering medication for prevention of ischemic events is reasonable for patients who have undergone CEA irrespective of serum lipid levels, although the optimum agent and dose and the efficacy for prevention of restenosis have not been established[32]. (Level of Evidence: B) "
"3. Noninvasive imaging of the extracranial carotid arteries is reasonable 1 month, 6 months, and annually after CEA to assess patency and exclude the development of new or contralateral lesions. Once stability has been established over an extended period, surveillance at longer intervals may be appropriate. Termination of surveillance is reasonable when the patient is no longer a candidate for intervention. (Level of Evidence: C) "
Management of Patients Undergoing Carotid Artery Stenting (DO NOT EDIT)[1]
"1. Before and for a minimum of 30 days after CAS, dual-antiplatelet therapy with aspirin (81 to 325 mg daily) plus clopidogrel (75 mg daily) is recommended. For patients intolerant of clopidogrel, ticlopidine (250 mg twice daily) may be substituted. (Level of Evidence: C) "
"2. Administration of antihypertensive medication is recommended to control blood pressure before and after CAS. (Level of Evidence: C) "
"3. The findings on clinical neurological examination should be documented within 24 hours before and after CAS. (Level of Evidence: C) "
"1. Embolic protection device (EPD) deployment during CAS can be beneficial to reduce the risk of stroke when the risk of vascular injury is low[33][34]. (Level of Evidence: C) "
"2. Noninvasive imaging of the extracranial carotid arteries is reasonable 1 month, 6 months, and annually after revascularization to assess patency and exclude the development of new or contralateral lesions. Once stability has been established over an extended period, surveillance at extended intervals may be appropriate. Termination of surveillance is reasonable when the patient is no longer a candidate for intervention. (Level of Evidence: C) "
Management of Patients Experiencing Restenosis After Carotid Endarterectomy or Stenting (DO NOT EDIT)[1]
"1. Reoperative CEA or CAS should not be performed in asymptomatic patients with less than 70% carotid stenosis that has remained stable over time. (Level of Evidence: C) "
"2. Reoperative CEA or CAS after initial revascularization is reasonable when duplex ultrasound and another confirmatory imaging method identify rapidly progressive restenosis that indicates a threat of complete occlusion. (Level of Evidence: C) "
"1. In asymptomatic patients who develop recurrent carotid stenosis due to intimal hyperplasia or atherosclerosis, reoperative CEA or CAS may be considered using the same criteria as recommended for initial revascularization. (Level of Evidence: C) "
Carotid Artery Evaluation and Revascularization Before Cardiac Surgery (DO NOT EDIT)[1]
"1. Carotid duplex ultrasound screening is reasonable before elective coronary artery bypass graft (CABG) surgery in patients older than 65 years of age and in those with left main coronary stenosis, PAD, a history of cigarette smoking, a history of stroke or TIA, or carotid bruit. (Level of Evidence: C) "
"2.Carotid revascularization by CEA or CAS with embolic protection before or concurrent with myocardial revascularization surgery is reasonable in patients with greater than 80% carotid stenosis who have experienced ipsilateral retinal or hemispheric cerebral ischemic symptoms within 6 months. (Level of Evidence: C) "
"1. In patients with asymptomatic carotid stenosis, even if severe, the safety and efficacy of carotid revascularization before or concurrent with myocardial revascularization are not well established. (Level of Evidence: C) "
↑ 2.02.1Barnett HJ, Taylor DW, Eliasziw M; et al. (1998). "Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators". N. Engl. J. Med. 339 (20): 1415–25. doi:10.1056/NEJM199811123392002. PMID9811916. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 3.03.13.2"Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST)". Lancet. 351 (9113): 1379–87. 1998. PMID9593407. Unknown parameter |month= ignored (help)
↑ 4.04.1Rothwell PM, Slattery J, Warlow CP (1996). "A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis". Stroke. 27 (2): 260–5. PMID8571420. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑ 6.06.1"Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study". JAMA. 273 (18): 1421–8. 1995. PMID7723155. Unknown parameter |month= ignored (help)
↑ 7.07.17.2Gurm HS, Yadav JS, Fayad P; et al. (2008). "Long-term results of carotid stenting versus endarterectomy in high-risk patients". N. Engl. J. Med. 358 (15): 1572–9. doi:10.1056/NEJMoa0708028. PMID18403765. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 8.08.1Bates ER, Babb JD, Casey DE; et al. (2007). "ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting)". J. Am. Coll. Cardiol. 49 (1): 126–70. doi:10.1016/j.jacc.2006.10.021. PMID17207736. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Hobson RW, Weiss DG, Fields WS; et al. (1993). "Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group". N. Engl. J. Med. 328 (4): 221–7. doi:10.1056/NEJM199301283280401. PMID8418401. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Gray WA, Hopkins LN, Yadav S; et al. (2006). "Protected carotid stenting in high-surgical-risk patients: the ARCHeR results". J. Vasc. Surg. 44 (2): 258–68. doi:10.1016/j.jvs.2006.03.044. PMID16890850. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Katzen BT, Criado FJ, Ramee SR; et al. (2007). "Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study". Catheter Cardiovasc Interv. 70 (2): 316–23. doi:10.1002/ccd.21222. PMID17630678. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Eckstein HH, Ringleb P, Allenberg JR; et al. (2008). "Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial". Lancet Neurol. 7 (10): 893–902. doi:10.1016/S1474-4422(08)70196-0. PMID18774746. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Chiam PT, Roubin GS, Panagopoulos G; et al. (2009). "One-year clinical outcomes, midterm survival, and predictors of mortality after carotid stenting in elderly patients". Circulation. 119 (17): 2343–8. doi:10.1161/CIRCULATIONAHA.108.805465. PMID19380623. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 16.016.116.2Roubin GS, New G, Iyer SS; et al. (2001). "Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis". Circulation. 103 (4): 532–7. PMID11157718. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 17.017.1Zahn R, Ischinger T, Hochadel M; et al. (2007). "Carotid artery stenting in octogenarians: results from the ALKK Carotid Artery Stent (CAS) Registry". Eur. Heart J. 28 (3): 370–5. doi:10.1093/eurheartj/ehl421. PMID17158826. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 19.019.1Gray WA, Yadav JS, Verta P; et al. (2007). "The CAPTURE registry: results of carotid stenting with embolic protection in the post approval setting". Catheter Cardiovasc Interv. 69 (3): 341–8. doi:10.1002/ccd.21050. PMID17171654. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 20.020.1Yadav JS, Wholey MH, Kuntz RE; et al. (2004). "Protected carotid-artery stenting versus endarterectomy in high-risk patients". N. Engl. J. Med. 351 (15): 1493–501. doi:10.1056/NEJMoa040127. PMID15470212. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Harrod-Kim P, Kadkhodayan Y, Derdeyn CP, Cross DT, Moran CJ (2005). "Outcomes of carotid angioplasty and stenting for radiation-associated stenosis". AJNR Am J Neuroradiol. 26 (7): 1781–8. PMID16091530. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ (2004). "Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery". Lancet. 363 (9413): 915–24. doi:10.1016/S0140-6736(04)15785-1. PMID15043958. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Safian RD, Bacharach JM, Ansel GM, Criado FJ (2004). "Carotid stenting with a new system for distal embolic protection and stenting in high-risk patients: the carotid revascularization with ev3 arterial technology evolution (CREATE) feasibility trial". Catheter Cardiovasc Interv. 63 (1): 1–6. doi:10.1002/ccd.20155. PMID15343559. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑White CJ, Iyer SS, Hopkins LN, Katzen BT, Russell ME (2006). "Carotid stenting with distal protection in high surgical risk patients: the BEACH trial 30 day results". Catheter Cardiovasc Interv. 67 (4): 503–12. doi:10.1002/ccd.20689. PMID16548004. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑"A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group". N. Engl. J. Med. 299 (2): 53–9. 1978. doi:10.1056/NEJM197807132990201. PMID351394. Unknown parameter |month= ignored (help)
↑Taylor DW, Barnett HJ, Haynes RB; et al. (1999). "Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators". Lancet. 353 (9171): 2179–84. PMID10392981. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee". Lancet. 348 (9038): 1329–39. 1996. PMID8918275. Unknown parameter |month= ignored (help)
↑Mohr JP, Thompson JL, Lazar RM; et al. (2001). "A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke". N. Engl. J. Med. 345 (20): 1444–51. doi:10.1056/NEJMoa011258. PMID11794192. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Bhatt DL, Fox KA, Hacke W; et al. (2006). "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events". N. Engl. J. Med. 354 (16): 1706–17. doi:10.1056/NEJMoa060989. PMID16531616. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑AbuRahma AF, Robinson PA, Saiedy S, Richmond BK, Khan J (1999). "Prospective randomized trial of bilateral carotid endarterectomies: primary closure versus patching". Stroke. 30 (6): 1185–9. PMID10356097. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Bond R, Rerkasem K, AbuRahma AF, Naylor AR, Rothwell PM (2004). "Patch angioplasty versus primary closure for carotid endarterectomy". Cochrane Database Syst Rev (2): CD000160. doi:10.1002/14651858.CD000160.pub2. PMID15106145.CS1 maint: Multiple names: authors list (link)
↑LaMuraglia GM, Stoner MC, Brewster DC; et al. (2005). "Determinants of carotid endarterectomy anatomic durability: effects of serum lipids and lipid-lowering drugs". J. Vasc. Surg. 41 (5): 762–8. doi:10.1016/j.jvs.2005.01.035. PMID15886657. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Garg N, Karagiorgos N, Pisimisis GT; et al. (2009). "Cerebral protection devices reduce periprocedural strokes during carotid angioplasty and stenting: a systematic review of the current literature". J. Endovasc. Ther. 16 (4): 412–27. doi:10.1583/09-2713.1. PMID19702342. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Andziak P (2006). "[Commentary to the articles: SPACE Collaborative Group. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368: 1239-47. Mas JL, Chatellier G, Beyssen B, et al. EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006; 355: 1660-71]". Kardiol Pol (in Polish). 64 (12): 1458–60, discussion 1460–1. PMID17206550. Unknown parameter |month= ignored (help)CS1 maint: Unrecognized language (link)